The Robot Report

  • Home
  • News
  • Technologies
    • Batteries / Power Supplies
    • Cameras / Imaging / Vision
    • Controllers
    • End Effectors
    • Microprocessors / SoCs
    • Motion Control
    • Sensors
    • Soft Robotics
    • Software / Simulation
  • Development
    • Artificial Intelligence
    • Human Robot Interaction / Haptics
    • Mobility / Navigation
    • Research
  • Robots
    • AGVs
    • AMRs
    • Consumer
    • Collaborative Robots
    • Drones
    • Exoskeletons
    • Industrial
    • Self-Driving Vehicles
    • Unmanned Maritime Systems
  • Markets
    • Agriculture
    • Healthcare
    • Logistics
    • Manufacturing
    • Mining
    • Security
  • Financial
    • Investments
    • Mergers & Acquisitions
    • Earnings
  • Resources
    • Careers
    • COVID-19
    • Digital Issues
    • Publications
      • Collaborative Robotics Trends
      • Robotics Business Review
    • RBR50 Winners 2022
    • Search Robotics Database
    • Videos
    • Webinars / Digital Events
  • Events
    • RoboBusiness
    • Robotics Summit & Expo
    • Healthcare Robotics Engineering Forum
    • DeviceTalks
    • R&D 100
    • Robotics Weeks
  • Podcast
    • Episodes
    • Leave a voicemail

Procept BioRobotics wins de novo nod from FDA for Aquabeam prostate treatment

By Brad Perriello | December 21, 2017

procept bioroboticsProcept BioRobotics said today that it won de novo clearance from the FDA for its Aquabeam device for treating benign prostate hyperplasia, saying it plans to have the device on the U.S. market early next year.

Redwood Shores, Calif.-based Procept said the federal safety watchdog used the 181-patient Water study to inform its decision. The trial, comparing Aquablation with transurethral resection of the prostate, showed equivalent efficacy and a better safety profile, including a reduction in sexual side effects by a ratio of four to one.

“FDA granted the de novo request just two years after treating the first patient in our U.S. pivotal trial. This is a remarkable achievement, and I congratulate our talented and dedicated team of employees, physicians and researchers, and everyone who worked tirelessly to make this significant milestone for our organization possible,” CEO Nikolai Aljuri said in prepared remarks. “We believe Aquablation therapy is poised to fundamentally transform the way physicians treat men suffering from BPH.”

“Until today, with current BPH treatment options, men have had to choose between significant symptom relief with a high risk of sexual side effects or a lower risk of sexual complications with less than adequate symptomatic benefit. For this reason, many men have avoided treatment altogether,” added co-principal investigator Dr. Claus Roehrborn of the University of Texas, Southwestern in Dallas. “Aquablation therapy breaks this trade-off in favor of the patient. Men can now benefit from significant symptom improvement alongside a low risk of sexual complications.”

“The Aquabeam system allows surgeons to determine an optimal tissue removal plan for each individual patient and achieve predictable, reproducible results, even in the case of larger prostates and prostates with obstructive median lobes,” noted co-principal investigator Dr. Peter Gilling of the University of Auckland, Bay of Plenty Clinical School Tauranga. “Additionally, the easy-to-use system coupled with autonomous robotic resection paves the way to the future of surgery by enabling consistent results, independent of surgeon experience.”

About The Author

Brad Perriello

Brad Perriello has written for The Associated Press, The Eagle-Tribune, Boston.com, The Boston Globe, Industrial Distribution magazine and a variety of local and regional newspapers. He received a master’s degree in journalism from Boston University in 2005. He helped co-found MassDevice and leads WTWH Media’s life science editorial team.

Comments

  1. Dick Molin says

    February 21, 2018 at 8:33 am

    Hello Brad, I see Procept just got some additional funding for their aquablation prostate robotic surgery. I enjoyed your Dec. article introducting the technology and wonder if in your research you obtained any information about the anticipated cost of the unit, anticipated competitiveness in the market, and if there is a part of the candidate population that would not be a target for this type of treatment. I’m sure you’re aware of the Urolift treatment (NeoTract) that is gaining momentum against the pure surgical treatments, and the other new steam ablation technology by NxThera. I’m wondering how Procept expects to stack up against them. And finally, do you know what their path to reimbursement looks like, i.e. have they telegraphed their progress down this path as it could be the telling variable to their level of success. Thanks and have a great day. Dick Molin [email protected]

    Reply

Tell Us What You Think! Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Related Articles Read More >

memic
Memic completes first U.S. cases with Hominis Surgical System
Ekso Bionics exoskeleton cleared for use with MS patients
moon surgical
Moon Surgical raises $31.3M for robotic surgery system
ElliQ
Intuition Robotics partners with NY State Office for the Aging

2021 Robotics Handbook

The Robot Report Listing Database

Latest Robotics News

Robot Report Podcast

Brian Gerkey from Open Robotics discusses the development of ROS
See More >

Sponsored Content

  • Magnetic encoders support the stabilization control of a self-balancing two-wheeled robotic vehicle
  • How to best choose your AGV’s Wheel Drive provider
  • Meet Trey, the autonomous trailer (un)loading forklift
  • Kinova Robotics launches Link 6, the first Canadian industrial collaborative robot
  • Torque sensors help make human/robot collaborations safer for workers

RBR50 Innovation Awards

Leave us a voicemail

The Robot Report
  • Mobile Robot Guide
  • Collaborative Robotics Trends
  • Field Robotics Forum
  • Healthcare Robotics Engineering Forum
  • RoboBusiness Event
  • Robotics Business Review
  • Robotics Summit & Expo
  • About The Robot Report
  • Subscribe
  • Advertising
  • Contact Us

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search The Robot Report

  • Home
  • News
  • Technologies
    • Batteries / Power Supplies
    • Cameras / Imaging / Vision
    • Controllers
    • End Effectors
    • Microprocessors / SoCs
    • Motion Control
    • Sensors
    • Soft Robotics
    • Software / Simulation
  • Development
    • Artificial Intelligence
    • Human Robot Interaction / Haptics
    • Mobility / Navigation
    • Research
  • Robots
    • AGVs
    • AMRs
    • Consumer
    • Collaborative Robots
    • Drones
    • Exoskeletons
    • Industrial
    • Self-Driving Vehicles
    • Unmanned Maritime Systems
  • Markets
    • Agriculture
    • Healthcare
    • Logistics
    • Manufacturing
    • Mining
    • Security
  • Financial
    • Investments
    • Mergers & Acquisitions
    • Earnings
  • Resources
    • Careers
    • COVID-19
    • Digital Issues
    • Publications
      • Collaborative Robotics Trends
      • Robotics Business Review
    • RBR50 Winners 2022
    • Search Robotics Database
    • Videos
    • Webinars / Digital Events
  • Events
    • RoboBusiness
    • Robotics Summit & Expo
    • Healthcare Robotics Engineering Forum
    • DeviceTalks
    • R&D 100
    • Robotics Weeks
  • Podcast
    • Episodes
    • Leave a voicemail